Add to Calendar 5/16/2019 8:00:00 AM 5/16/2019 10:00:00 AM Exploration of Non-traditional Therapeutics: Antibody Drug Conjugates
With over 30 years of R&D history, Antibody-drug Conjugates combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. Their goal is to transport “deactivated” toxic agents to targeted cancer cells without adversely affecting normal tissues. Once in the tumor cell the cytotoxin’s full cancer killing capability is activated causing rapid cell death. Although it sounds simple these therapies are complex and throughout its history and ongoing research is focused on optimizing the components and the resultant whole in terms of its ability to target the right cells and deliver the most effective knockout punch to cancer cells.
Our distinguished panel of experts will cover:
  • Why ADCs?
  • Latest ADC approaches to speed component selection and testing
  • Modern techniques to ensure stability, targeted delivery, and limited off-target effects
  • Working with FDA to create a joint understanding of how their therapies work and accelerate time to clinical trials
  • Where are we going? The application of ADCs beyond oncology and hematology to other important disease areas
NOTE: This forum will be held at the Ragon Institute Auditorium, 400 Technology Square which is adjacent to the MassBio offices which are at 300 Technology Square.
 Ragon Auditorium, 400 Tech Square, Cambridge, MA 02139
Director Preclinical Safety, Novartis
Anu Connor is a board certified toxicologist, graduating from Northeastern University with a PhD in Biomedical Sciences with a specialization in Toxicology. After graduation, she joined Sepracor in Marlborough MA as a toxicologist developing CNS small molecules. She then moved to the west coast and spent several years in the Bay Area at Genentech as a scientist and pharmacology subteam leader in the biotherapeutics group. She has been working on ADC development since 2008 at broad range of companies, spanning from start up to large pharma. She is currently a Director at Novartis in the Preclinical Safety Group and is responsible for the oversight and strategic development of multiple oncology platforms.